Company intelligence / Profile preview

Amaxa

Cologne, North Rhine-Westphalia, Germany

Ownership: Private
Employees: ~160
Development stage: Other

Overview

Amaxa was a German biotechnology company specializing in highly efficient, non-viral gene transfer into primary cells and hard-to-transfect cell lines. The company is best known for developing the Nucleofector technology, an advanced electroporation-based method that allows for the direct delivery of DNA or RNA into the cell nucleus. This technology became a standard tool in research and drug discovery, particularly for immunology and oncology applications. In 2008, Amaxa was acquired by Lonza Group, where its products continue to be marketed under the Lonza brand.

Modalities: Cell therapyGene therapymRNA-based drugsSmall interfering RNA
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Amaxa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amaxa.

Explore the full profile